Cargando…

TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling

Treatment of schistosomiasis relies precariously on just one drug, praziquantel (PZQ). In the search for alternatives, 15 S-[2-(alkylamino)alkane] thiosulfuric acids were obtained from a previous research program and profiled in mice for efficacy against both mature (>42-day-old) and juvenile (21...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfe, Alan R., Neitz, R. Jeffrey, Burlingame, Mark, Suzuki, Brian M., Lim, KC, Scheideler, Mark, Nelson, David L., Benet, Leslie Z., Caffrey, Conor R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287543/
https://www.ncbi.nlm.nih.gov/pubmed/30503203
http://dx.doi.org/10.1016/j.ijpddr.2018.10.004
_version_ 1783379658865115136
author Wolfe, Alan R.
Neitz, R. Jeffrey
Burlingame, Mark
Suzuki, Brian M.
Lim, KC
Scheideler, Mark
Nelson, David L.
Benet, Leslie Z.
Caffrey, Conor R.
author_facet Wolfe, Alan R.
Neitz, R. Jeffrey
Burlingame, Mark
Suzuki, Brian M.
Lim, KC
Scheideler, Mark
Nelson, David L.
Benet, Leslie Z.
Caffrey, Conor R.
author_sort Wolfe, Alan R.
collection PubMed
description Treatment of schistosomiasis relies precariously on just one drug, praziquantel (PZQ). In the search for alternatives, 15 S-[2-(alkylamino)alkane] thiosulfuric acids were obtained from a previous research program and profiled in mice for efficacy against both mature (>42-day-old) and juvenile (21-day-old) Schistosoma mansoni using a screening dose of 100 mg/kg PO QDx4. One compound, S-[2-(tert-butylamino)-1-phenylethane] thiosulfuric acid (TPT sulfonate), was the most effective by decreasing female and male worm burdens by ≥ 90% and ≥46% (mature), and ≥89% and ≥79% (juvenile), respectively. In contrast, PZQ decreased mature female and male worm burdens by 95% and 94%, respectively, but was ineffective against juvenile stages. Against 7-day-old lung-stage worms, TPT sulfonate was only effective at twice the dose decreasing female and male burdens by 95 and 80%, respectively. Single oral doses at 400 and/or 600 mg/kg across various developmental time-points (1-, 7-, 15-, 21- and/or 42 day-old) were consistent with the QD x4 data; efficacy was strongest once the parasites had completed lung migration, and female and male burdens were decreased by at least 90% and 80%, respectively. In vitro, TPT sulfonate is inactive against the parasite suggesting a pro-drug mechanism of action. In mice, TPT sulfonate is fully absorbed and subject to rapid, non-CYP-mediated, first-pass metabolism that is initiated by desulfation and yields a series of metabolites. The initially-formed free thiol-containing metabolite, termed TP thiol, was chemically synthesized; it dose-dependently decreased S. mansoni and Schistosoma haematobium motility in vitro. Also, when administered as a single 50 mg/kg IP dose, TP thiol decreased 33-day-old S. mansoni female and male burdens by 35% and 44%, with less severe organomegaly. Overall, TPT sulfonate's efficacy profile is competitive with that of PZQ. Also, the characterization of a parasiticidal metabolite facilitates an understanding and improvement of the chemistry, and identification of the mechanism of action and/or target.
format Online
Article
Text
id pubmed-6287543
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62875432018-12-19 TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling Wolfe, Alan R. Neitz, R. Jeffrey Burlingame, Mark Suzuki, Brian M. Lim, KC Scheideler, Mark Nelson, David L. Benet, Leslie Z. Caffrey, Conor R. Int J Parasitol Drugs Drug Resist Articles from the scientific meeting: "Anthelmintics: From Discovery to Resistance III", pp. 494 - 628. Treatment of schistosomiasis relies precariously on just one drug, praziquantel (PZQ). In the search for alternatives, 15 S-[2-(alkylamino)alkane] thiosulfuric acids were obtained from a previous research program and profiled in mice for efficacy against both mature (>42-day-old) and juvenile (21-day-old) Schistosoma mansoni using a screening dose of 100 mg/kg PO QDx4. One compound, S-[2-(tert-butylamino)-1-phenylethane] thiosulfuric acid (TPT sulfonate), was the most effective by decreasing female and male worm burdens by ≥ 90% and ≥46% (mature), and ≥89% and ≥79% (juvenile), respectively. In contrast, PZQ decreased mature female and male worm burdens by 95% and 94%, respectively, but was ineffective against juvenile stages. Against 7-day-old lung-stage worms, TPT sulfonate was only effective at twice the dose decreasing female and male burdens by 95 and 80%, respectively. Single oral doses at 400 and/or 600 mg/kg across various developmental time-points (1-, 7-, 15-, 21- and/or 42 day-old) were consistent with the QD x4 data; efficacy was strongest once the parasites had completed lung migration, and female and male burdens were decreased by at least 90% and 80%, respectively. In vitro, TPT sulfonate is inactive against the parasite suggesting a pro-drug mechanism of action. In mice, TPT sulfonate is fully absorbed and subject to rapid, non-CYP-mediated, first-pass metabolism that is initiated by desulfation and yields a series of metabolites. The initially-formed free thiol-containing metabolite, termed TP thiol, was chemically synthesized; it dose-dependently decreased S. mansoni and Schistosoma haematobium motility in vitro. Also, when administered as a single 50 mg/kg IP dose, TP thiol decreased 33-day-old S. mansoni female and male burdens by 35% and 44%, with less severe organomegaly. Overall, TPT sulfonate's efficacy profile is competitive with that of PZQ. Also, the characterization of a parasiticidal metabolite facilitates an understanding and improvement of the chemistry, and identification of the mechanism of action and/or target. Elsevier 2018-11-20 /pmc/articles/PMC6287543/ /pubmed/30503203 http://dx.doi.org/10.1016/j.ijpddr.2018.10.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles from the scientific meeting: "Anthelmintics: From Discovery to Resistance III", pp. 494 - 628.
Wolfe, Alan R.
Neitz, R. Jeffrey
Burlingame, Mark
Suzuki, Brian M.
Lim, KC
Scheideler, Mark
Nelson, David L.
Benet, Leslie Z.
Caffrey, Conor R.
TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling
title TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling
title_full TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling
title_fullStr TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling
title_full_unstemmed TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling
title_short TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling
title_sort tpt sulfonate, a single, oral dose schistosomicidal prodrug: in vivo efficacy, disposition and metabolic profiling
topic Articles from the scientific meeting: "Anthelmintics: From Discovery to Resistance III", pp. 494 - 628.
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287543/
https://www.ncbi.nlm.nih.gov/pubmed/30503203
http://dx.doi.org/10.1016/j.ijpddr.2018.10.004
work_keys_str_mv AT wolfealanr tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling
AT neitzrjeffrey tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling
AT burlingamemark tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling
AT suzukibrianm tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling
AT limkc tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling
AT scheidelermark tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling
AT nelsondavidl tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling
AT benetlesliez tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling
AT caffreyconorr tptsulfonateasingleoraldoseschistosomicidalprodruginvivoefficacydispositionandmetabolicprofiling